Clinical trials: Rosuvastatin, active
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Hypertension, Dyslipidemias
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive…
- Trial name
- NCT05660135
- Testing
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Carotid Stenosis
Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque
CAROTID-STABILISE is a phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating whether alirocumab 150 mg subcutaneously every 2 weeks, added to high-intensity statin therapy, produces greater…
- Trial name
- CAROTID-STABIL (NCT07586540)
- Testing
- Alirocumab, Atorvastatin
- Where
- 14 sites in Egypt, Jordan and 6 more
- Volunteers
- 280 people
- Sponsor
- Middle East North Africa Stroke and Interventional Neurotherapies Organization
Ischemic Stroke, TIA
Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study
Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients.
- Trial name
- SAFEST-coh (NCT06785740)
- Testing
- Statin
- Where
- 4 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Healthy Adult Participants
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
This study will enroll healthy participants to evaluate whether BGB-43395 interacts with other drugs, including midazolam, celecoxib, dabigatran, and rosuvastatin.
- Trial name
- NCT07820891
- Testing
- BGB-43395, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Erectile Dysfunction Due to Arterial Disease, Atheroscleroses
TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men
Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk.
- Conditions
- Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction, Endothelial Dysfunction
- Trial name
- NCT07460960
- Testing
- Pitavastatin 1-4 mg daily, Rosuvastatin 20-40 mg daily
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Lomonosov Moscow State University Medical Research and Educational Center
Venous Thromboembolism, Blood Clot
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants).
- Conditions
- Venous Thromboembolism, Blood Clot, Post Thrombotic Syndrome
- Trial name
- SAVER (NCT04319627)
- Testing
- Rosuvastatin Calcium
- Where
- 31 sites in Canada, France and 4 more
- Volunteers
- 2,700 people
- Sponsor
- Ottawa Hospital Research Institute
Chronic Intracranial Artery Occlusion
Endovascular Treatment of Chronic Intracranial Artery Occlusion
Comparison of the efficacy and safety of endovascular treatment versus medical treatment in patients with chronic intracranial artery occlusion.
- Trial name
- NCT07699003
- Testing
- Endovascular treatment, Standard pharmacological treatment
- Volunteers
- 382 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Coronary Artery Disease
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective…
- Trial name
- WARRIOR (NCT03417388)
- Testing
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 2,476 people
- Sponsor
- Cedars-Sinai Medical Center
Dyslipidemia Associated With Type II Diabetes Mellitus
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C).
- Trial name
- NCT07359105
- Testing
- Moderate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
- Where
- 2 sites in South Korea
- Volunteers
- 2,186 people
- Sponsor
- Sin Gon Kim
Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
For Patients and Families Brief Title: Management of 1L Lorlatinib with Hyperlipidemia in ALK+ Advanced NSCLC What is this study about? This study is for people with ALK-positive non-small cell lung cancer (NSCLC) who are taking…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia, ALK Gene Mutation, ALK-positive
- Trial name
- NCT07674524
- Testing
- For Part A - Observational Cohort:, Part B: Intensive Lipid-Lowering Group, For Part B - Intensive Group
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin.
- Trial name
- NCT07216482
- Testing
- Enlicitide, Rosuvastatin
- Where
- 87 sites in United States, Argentina and 9 more
- Volunteers
- 996 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Diseases (CVD), Drug Effect
Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial
Statins inhibit hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyzes the rate-limiting step in cholesterol synthesis.
- Conditions
- Cardiovascular Diseases (CVD), Drug Effect, Atherosclerosis Cardiovascular Disease
- Trial name
- STATIN-C3 (NCT06856772)
- Testing
- Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
- Where
- Denmark
- Volunteers
- 42,000 people
- Sponsor
- Tor Biering-Sørensen
ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a multicenter, open-label, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic /pharmacodynamic characteristics of SIM0518 in trial participants with ALK-positive or ROS1-positive…
- Trial name
- NCT07912268
- Testing
- SIM0518, SIM0518+Bupropion, SIM0518+Midazolam
- Where
- 8 sites in China
- Volunteers
- 270 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
PRS-based Primary Prevention of CVD
Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention
This research investigates the potential advantages of intensive preventive statin treatment for healthy men aged 45-80 and women aged 55-80 who possess a high genetic predisposition to coronary artery disease (CAD).
- Trial name
- EE-PRS (NCT06820086)
- Testing
- Rosuvastatin 20mg
- Where
- 2 sites in Estonia
- Volunteers
- 2,714 people
- Sponsor
- Mikk JÜRISSON
Ischemic Stroke, Atherosclerosis of Artery
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed…
- Conditions
- Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder, Statin
- Trial name
- EPCIS (NCT06604117)
- Testing
- Statin, Probucol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xuanwu Hospital, Beijing
Chronic Coronary Syndrome
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C <1.0 mmol/L and ≥50% reduction frome baseline) could delay progression of coronary…
- Trial name
- CAPITAL-PLAQUE (NCT06896708)
- Testing
- Intensive lipid-lowering strategy, Standard lipid-lowering strategy
- Where
- 7 sites in China
- Volunteers
- 766 people
- Sponsor
- Liu yong
Hypercholesterolaemia
LATAM LOWERS LDL-C
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and…
- Trial name
- NCT06501443
- Testing
- Usual care, KJX839
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 520 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and…
- Trial name
- NCT07629999
- Testing
- BMS-986533, Famotidine, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb